|
|
|
|
||
Re: JMP - CELG: Celgene Returns Rights to MOR202 to MorphoSys It is a hit in as much as CELG would prefer to wholly own a drug class that will mark the next leap forward in MM treatment. Revlimid will be fine but you would want CELG to stay ahead of the treatment curve with the next generation of drugs. So yes, they decided that the morphosys drug was not worth it but have an anti-cd38 drug is still important, so losing in that race is a hit. |
return to message board, top of board |